Covaxin Maker Bharat Biotech’s Nasal Booster Dose Trials Get Approval

New Delhi: 

Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin. The Drug Controller General of India today gave the go-ahead for the Phase-III trials. The trials will be conducted at nine locations in the country.

An intranasal vaccine as a booster will be easier to administer in mass vaccination drives.

Bharat Biotech has said that the nasal vaccine, BBV154, stimulates immune responses at the site of infection — the nose — and is very effective in blocking infection and transmission of Covid-19.